Nothing Special   »   [go: up one dir, main page]

ES2578729T3 - Agente terapéutico para enfermedades relacionadas con el hígado - Google Patents

Agente terapéutico para enfermedades relacionadas con el hígado Download PDF

Info

Publication number
ES2578729T3
ES2578729T3 ES10812011.4T ES10812011T ES2578729T3 ES 2578729 T3 ES2578729 T3 ES 2578729T3 ES 10812011 T ES10812011 T ES 10812011T ES 2578729 T3 ES2578729 T3 ES 2578729T3
Authority
ES
Spain
Prior art keywords
therapeutic agent
related diseases
liver related
liver
vein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10812011.4T
Other languages
English (en)
Inventor
Akifumi Matsuyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka Air Machine Service Ltd
Original Assignee
Osaka Air Machine Service Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka Air Machine Service Ltd filed Critical Osaka Air Machine Service Ltd
Application granted granted Critical
Publication of ES2578729T3 publication Critical patent/ES2578729T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Un agente terapéutico que comprende células progenitoras multilinaje derivadas de tejido adiposo para su uso en el tratamiento de una enfermedad relacionada con el hígado, donde el agente es para administrar a través de la vena porta, a través de una vena, a través de una arteria, o a través de un conducto biliar.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9

Claims (1)

  1. imagen1
ES10812011.4T 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado Active ES2578729T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009198166 2009-08-28
JP2009198166 2009-08-28
PCT/JP2010/064623 WO2011024962A1 (ja) 2009-08-28 2010-08-27 肝臓関連疾患治療薬

Publications (1)

Publication Number Publication Date
ES2578729T3 true ES2578729T3 (es) 2016-07-29

Family

ID=43628060

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10812011.4T Active ES2578729T3 (es) 2009-08-28 2010-08-27 Agente terapéutico para enfermedades relacionadas con el hígado

Country Status (5)

Country Link
US (1) US8784803B2 (es)
EP (1) EP2471542B1 (es)
JP (1) JP4965000B2 (es)
ES (1) ES2578729T3 (es)
WO (1) WO2011024962A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2600321T3 (es) * 2011-08-04 2017-02-08 Ethianum Betriebsgesellschaft Mbh & Co. Kg Medios para la regeneración del hígado
US9533013B2 (en) * 2013-03-13 2017-01-03 University Of North Carolina At Chapel Hill Method of treating pancreatic and liver conditions by endoscopic-mediated (or laparoscopic-mediated) transplantation of stem cells into/onto bile duct walls of particular regions of the biliary tree
WO2016167977A1 (en) 2015-04-14 2016-10-20 Mayo Foundation For Medical Education And Research Methods and materials for delivering agents to liver tissue
JP6923137B2 (ja) * 2018-06-15 2021-08-18 有限会社大阪空気機械サービス 組織治癒剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU749675B2 (en) * 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US20030082152A1 (en) * 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
EP2308963A3 (en) * 2001-12-07 2011-09-21 Cytori Therapeutics, Inc. System for processing lipoaspirate cells
ES2257225B1 (es) * 2006-02-17 2007-03-16 Grifols, S.A Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion.
AU2007244965A1 (en) 2006-04-25 2007-11-08 Artecel, Inc. Adipose derived adult stem cells in hepatic regeneration
CN101501710A (zh) 2006-08-03 2009-08-05 智能包装技术公司 特别是电子护照的保密性增强的安全文件
US9845458B2 (en) 2007-06-14 2017-12-19 Akifumi Matsuyama Multipotent progenitor cell derived from adipose tissue
JP5338322B2 (ja) 2008-01-11 2013-11-13 ダイキン工業株式会社 空気調和装置の室内ユニット

Also Published As

Publication number Publication date
EP2471542B1 (en) 2016-04-27
WO2011024962A1 (ja) 2011-03-03
JP4965000B2 (ja) 2012-07-04
EP2471542A4 (en) 2013-11-20
US8784803B2 (en) 2014-07-22
JPWO2011024962A1 (ja) 2013-01-31
EP2471542A1 (en) 2012-07-04
US20120156181A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
PH12021550328A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
CL2011003094A1 (es) Composicion farmaceutica semi-solida libre de agua que comprende a) un ester del acido 5-aminolevulinico (5-ala) o una sal del mismo, b) uno o mas trigliceridos y c) opcionalmente uno o mas potenciadores de viscosidad; kit farmaceutico; y su uso en el tratamiento fotodinamico del cancer, condiciones pre-cancerosas y no cancerosas asociadas a hpv.
CR11749A (es) Tratamiento de la disnea asociada con insuficiencia cardiaca aguda con relaxina
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
MX394764B (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
ES2578729T3 (es) Agente terapéutico para enfermedades relacionadas con el hígado
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
ES2552654T3 (es) Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos
AR103415A1 (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
SG10201804772UA (en) Method of imaging living tissue
RU2012131164A (ru) (метилсульфонил)этил-бензол-изоиндолиновые производные и их терапевтическое применение
AR084216A1 (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit
IT1398773B1 (it) Sequenze oligonucleotidiche inibitrici dell'espressione della chimera ciclina d1/trop2 e loro uso in campo medico.
UY32414A (es) Nuevos metodos
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
BR112015017040A2 (pt) aumento de volume muscular em um ser humano com o uso de ácido hialurônico
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso